Valion Bio (VBIO) Financials: Revenue & Earnings
VBIO$0.63-0.05 -7.12%
$1.32M
Market Cap
—
P/E
—
Forward P/E
—
Score
Valion Bio (VBIO) Financials: Revenue & Earnings
VBIO price $0.63 -0.05 -7.12%
- Ticker
- VBIO
- Price
- $0.63
- Change
- -0.05 -7.12%
- Market cap ?
- $1.32M
- Sector
- Healthcare
- Industry
- Biotechnology
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it…
Earnings and financials
Valion Bio, Inc. (VBIO) trades at $0.63, with a market cap of $1.32M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn